Sana-Krankenhaus Hürth
    Hospital
    
    
        Location: 
        Hürth,
        
                Germany (DE)
                
    
        
    
    
        ISNI: 000000405805975
    
    
    
    
    
    
        
    
        
    
        
    
    
    
        
            
                
  
  Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021)
  Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al.
  Journal article
            
                
  
  Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant geparsepto trial (2019)
  Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al.
  Journal article